TherapeuticsMD (Nasdaq:TXMD) - Aandelenkoers, Nieuws & Analyse

TXMD Overzicht aandelen

TherapeuticsMD, Inc. is een farmaceutisch royaltybedrijf in de Verenigde Staten. Meer informatie

TXMD fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $16M )

Heeft geen zinvolle omzet ( $2M )

TherapeuticsMD, Inc. Concurrenten

Cumberland Pharmaceuticals

NasdaqGS:CPIX

US$14.9m

LiveCare

OTCPK:LVCE

US$17.1m

Traws Pharma

NasdaqCM:TRAW

US$13.5m

Aytu BioPharma

NasdaqCM:AYTU

US$10.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor TherapeuticsMD
Historische aandelenkoersen
Huidige aandelenkoers	US$1.37
52 Week Hoogtepunt	US$2.99
52 Week Laag	US$1.15
Bèta	1.14
11 maand verandering	-13.84%
3 maanden verandering	-28.65%
1 Jaar Verandering	-50.90%
33 jaar verandering	-95.19%
5 jaar verandering	-98.87%
Verandering sinds IPO	-97.26%

Recent nieuws en updates

Recent updates

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Jul 06

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

Jun 16

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Mar 14

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Oct 22

TherapeuticsMD: The Long Road To Profitability

Jul 08

TherapeuticsMD drops 3% despite consensus beating Q1 results

May 06

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

Feb 24

TherapeuticsMD: Annovera May Save The Day

Feb 04

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

Jan 29

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Jan 27

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

Dec 30

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Dec 09

TherapeuticsMD: Q3 Report Reveals Strong Rebound And Bolsters Commercial Outlook

Nov 25

Therapeutics MD EPS beats by $0.01, beats on revenue

Nov 09

Rendement voor aandeelhouders

	TXMD	US Pharmaceuticals	US Markt
7D	6.2%	1.6%	2.2%
1Y	-50.9%	9.9%	31.6%

Rendement versus industrie: TXMD presteerde slechter dan de US Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.9 % opleverde.

Rendement versus markt: TXMD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.

Prijsvolatiliteit

Is TXMD's price volatile compared to industry and market?
TXMD volatility
TXMD Average Weekly Movement	5.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: TXMD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van TXMD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2008	1	Marlan Walker	www.therapeuticsmd.com

TherapeuticsMD, Inc. is een farmaceutisch royaltybedrijf in de Verenigde Staten. Het heeft een licentieovereenkomst met Mayne Pharma voor de commercialisering van de voorgeschreven prenatale vitamineproducten IMVEXXY, BIJUVA en ANNOVERA, die worden verkocht onder de merknamen BocaGreenMD en vitaMedMD. Het bedrijf verkoopt zijn farmaceutische producten op recept en prenatale vitamineproducten via groothandelaars en distributeurs van apotheken.

TherapeuticsMD, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van TherapeuticsMD zich tot de beurswaarde?
TXMD fundamentele statistieken
Marktkapitalisatie	US$15.80m
Inkomsten(TTM)	-US$3.97m
Inkomsten(TTM)	US$1.60m

9.9x

P/S-verhouding

-4.0x

Koers/Winstverhouding

Is TXMD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TXMD resultatenrekening (TTM)
Inkomsten	US$1.60m
Kosten van inkomsten	US$0
Brutowinst	US$1.60m
Overige uitgaven	US$5.56m
Inkomsten	-US$3.97m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.34
Brutomarge	100.00%
Nettowinstmarge	-248.56%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde TXMD op de lange termijn?

Bekijk historische prestaties en vergelijking

TXMD Overzicht aandelen

Risicoanalyse

TherapeuticsMD, Inc. Concurrenten

NasdaqGS:CPIX

US$14.9m

OTCPK:LVCE

US$17.1m

NasdaqCM:TRAW

US$13.5m

NasdaqCM:AYTU

US$10.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD raises $7M in private placement

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

Therapeutics MD Q2 Earnings Preview

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD jumps 12% as top investor discloses insider purchase

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD plunges 42% as merger agreement ends

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Consensus forecasts updated

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Consensus forecasts updated

Price target decreased to US$3.75

Co-Founder notifies of intention to sell stock

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Co-Founder notifies of intention to sell stock

Consensus revenue estimates fall by 24%

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought US$579k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought US$725k worth of stock

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

No longer forecast to breakeven

TherapeuticsMD: The Long Road To Profitability

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

Co-Founder exercised options and sold US$70k worth of stock

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

TherapeuticsMD drops 3% despite consensus beating Q1 results

Revenue and earnings beat expectations

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

TherapeuticsMD: Annovera May Save The Day